 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678 |
- Livtencity (maribavir) / Takeda, GSK
Enrollment open: Study of SHP620 (Maribavir) in Healthy Adults (clinicaltrials.gov) - Aug 25, 2016
P1, N=18, Recruiting, Sponsor: Shire
Not yet recruiting --> Recruiting
- | Livtencity (maribavir) / Takeda, GSK
New P1 trial: Study of SHP620 (Maribavir) in Healthy Adults (clinicaltrials.gov) - May 18, 2016
P1, N=18, Not yet recruiting, Sponsor: Shire
- || Livtencity (maribavir) / Takeda, GSK
Trial primary completion date: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients (clinicaltrials.gov) - Mar 10, 2015
P2, N=120, Completed, Sponsor: Shire
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Dec 2014
- |||| Livtencity (maribavir) / Takeda, GSK
Trial completion: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients (clinicaltrials.gov) - Mar 7, 2015
P2, N=120, Completed, Sponsor: Shire
Trial primary completion date: Sep 2014 --> Dec 2014 Active, not recruiting --> Completed
- ||| Livtencity (maribavir) / Takeda, GSK
Enrollment closed: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients (clinicaltrials.gov) - Mar 23, 2014
P2, N=120, Active, not recruiting, Sponsor: Shire
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Livtencity (maribavir) / Takeda, GSK
New P2 trial: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients (clinicaltrials.gov) - Jun 3, 2012
P2, N=120, Active, not recruiting, Sponsor: Shire
- | Livtencity (maribavir) / Takeda, GSK
New P2 trial: A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patients (EUDRACT) - Feb 1, 2012
P2, N=160, Ongoing, Sponsor: VIROPHARMA INCORPORATED